Mo Sophy, Friedmann Dominique
Department of Medicine, Dermatology Service, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
SAGE Open Med Case Rep. 2024 Feb 14;12:2050313X241231491. doi: 10.1177/2050313X241231491. eCollection 2024.
Janus kinase (JAK) inhibitors are novel molecules increasingly prescribed for various dermatologic conditions. However, the Food and Drug Administration recently reported increased risks of malignancy in patients taking this class of medication. To shed more light on this potential adverse effect, we present a patient with cutaneous T-cell lymphoma possibly associated with his treatment with a JAK inhibitor for atopic dermatitis. To our knowledge, there are no reported cases of cutaneous T-cell lymphoma in association with JAK inhibitors in the literature. We highlight the importance of remaining cautious when prescribing this new class of medication, especially in patients with risk factors for malignancy. Moreover, when faced with atypical presentations of atopic dermatitis, we stress the need for a biopsy to make the correct diagnosis prior to treatment. Lastly, we encourage further studies to better characterize the malignancy risk associated with JAK inhibitors.
Janus激酶（JAK）抑制剂是一类新型药物，越来越多地被用于治疗各种皮肤病。然而，美国食品药品监督管理局最近报告称，服用这类药物的患者患恶性肿瘤的风险增加。为了更深入了解这种潜在的不良反应，我们报告了一名皮肤T细胞淋巴瘤患者，其可能与他使用JAK抑制剂治疗特应性皮炎有关。据我们所知，文献中尚无与JAK抑制剂相关的皮肤T细胞淋巴瘤病例报告。我们强调在开具这类新药时保持谨慎的重要性，尤其是对于有恶性肿瘤风险因素的患者。此外，当面对特应性皮炎的非典型表现时，我们强调在治疗前需要进行活检以做出正确诊断。最后，我们鼓励进一步研究，以更好地描述与JAK抑制剂相关的恶性肿瘤风险。
